INKLUDERING GJENNOM AKTIVITET Aquagroup AS er et norsk-eid konsern som ble stiftet i 2016. Selskapet har spesialisert oss innen ulike bransjer innen service og salg. Vårt hovedfokus er å tilby inkludering gjennom aktivitet ved å tilby ansatte med kunnskap og servicegrad innen de ulike bransjene vi oprerer i.

Renteradar monitors our users' mortgage rates over time and compares them to the offers available in the market. We want to make the process of monitoring and comparing mortgage rates as easy as possible by creating transparency. We automatically match our users with their cheapest lenders as well as assist in the following transition. Our system uses BankID to collect the required information which makes the experience as effortless and uncomplicated as possible.

OncoImmunity is a bioinformatics company providing unique machine-learning software to identify tumor-specific mutations that can be targeted by a patient’s own immune system (known as neoantigens). The OncoImmunity solution is important because recent breakthroughs in the field of Immuno-Oncology (I-O) such as the development of checkpoint inhibitors and personalized cancer vaccines, clearly demonstrate that a patient’s immune system can be harnessed to successfully treat cancer. The cost of identifying tumor-specific mutations in a patient’s cancer using next-generation sequencing (NGS) is now trivial and this technology will be key to enabling truly personalized immunotherapies to be developed in a technically and economically feasible manner. However, the remaining challenge that currently limits the field, and which is addressed by the OncoImmunity solution, is predicting which tumor-specific mutations can stimulate a patient’s immune system i.e. are immunogenic. Using NGS data as input, the OncoImmunity software enables accurate patient selection for cancer immunotherapy and can identify optimal targets for personalized cancer vaccines & cell therapies in a clinically actionable time frame. Beginning from this first product offering, OncoImmunity has the vision to become the world’s leading provider of software to guide cancer immunotherapy to improve survival rates for cancer patients. To achieve this OncoImmunity has assembled a growing team of world-class bioinformaticians, data scientists, and software engineers; developing its cutting-edge machine-learning technology that will help fulfill the promise of immunotherapy in the fight against cancer. OncoImmunity’s technology will disrupt the I-O field by offering regulatory-compliant prediction software on a software-as-a-service basis (SaaS). This will allow big pharma, biotechnology, and immunotherapy companies of any size to access OncoImmunity’s cutting-edge prediction software. The company is headquartered in an ideal scientific and entrepreneurial ecosystem to develop its technology at the Oslo Cancer Cluster Incubator; adjacent to the Institute for Cancer Research and the Norwegian Radium Hospital. OncoImmunity is a privately held company, founded in 2014 by experienced bioinformatics scientists (Dr. Trevor Clancy and Professor Eivind Hovig), and an experienced immunologist with a business development background (Dr. Richard Stratford). The company is backed by private financing from the Norwegian Radium Hospital Research Foundation, the Norwegian Cancer Society, STARTUPLAB, and Grotmol Solutions, in addition to a number of private software investors. The company is also supported by grants awarded from the Norwegian Research Council, Innovation Norway, and the EU. The company has already established both national and international collaborations and pilot projects to develop further proof-of-concept data and validate its software.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

The Norgeskart app for iPhone and iPad is the most detailed map of Norway. Norgeskart is suitable for hikers, tourists, and city walkers. • Comprehensive, accurate maps of Norway are delivered by Kartverket • Download the map for offline use • GPS navigation with auto-rotating map and compass • Search for places and addresses • Detailed trails for hiking, biking, and walking • Accurate sea maps along the Norwegian coast • Ad-free experience

Norwegian Oil & Gas Company was founded in 2016. Nor Oil Tools provide innovative tools to both simplify operations and cut costs without changing your whole process. Allowing you to cut your pipes, reduce your costs and improve your HSE. The Nor Tubular Cutter (NTC 325-10S) is the first tool to be released by Noroiltools and was launched in late 2017.

UVision makes sensors for underwater inspection - Visualising the subsea. Ships, harbours, windmills and bridges need regular inspection, also underwater, in order to avoid major failures and costly repairs. Underwater, inspection becomes a lot more complex, it is difficult and risky to operate under water, and video-inspections are costly and ineffective. We are therefor building the UVision sensor to make inspections easy, safe and precise. The UVision sensor is a 3D-underwater camera; unique in size and weight and therefore easy to mount on a pole, on any underwater drone or handheld by a diver. You scan an object by simply moving the sensor around it, guided by a real-time 3D-map on a screen. After the scan, advanced algorithms create a photorealistic 3D-model and store it in our cloud solution - ideal for collaboration with colleagues, customers and partners. We are three full-time founders - each with 25 years of experience within technology development, marketing and management. One of us has a lot of experience with underwater photography, and we all have a deep interest in technology and strong urge to make something of our own - with all the ups and downs it will bring :-)

EFUEL is on a mission to help people consume energy in a more sustainable and efficient way. We’re building Electric Vehicle charging networks by selling hardware and building services around that hardware. Our goal is to enable our customers to use the resources available in the electricity grid in a way that’s great for the environment, at a lower cost, gets the job done as efficiently as ever, and on top of that, is easy to understand and fun to use. A challenging task, but we’re making a serious effort to solve those challenges better than the competition. We’re a small company with a very warm, kind, and welcoming culture. Right now we’re growing fast and the coming year will see a lot of interesting and fun changes.

By digitalize the consumers wardrobe, we provide the consumers with a structured and categorized view of their wardrobe. The user can organize their clothing into digital, customized drawers, put together new outfits, schedule outfits forward, get statistics on their style and spending and see eachothers wardrobes, so it will be easier to share and borrow clothes from eachother. We're launching start november 2022 and already pre-launch we have over 5300K sign ups and above 32K followers on Tiktok.

Sereluna designs and sells its own menstrual underwear for the Norwegian market. We are the first menstrual underwear brand in Norway. Menstrual underwear has built in protection and is designed to be washed and reused for several years. Menstrual underwear completely replaces disposable protection like pads and tampons. The reason why Sereluna was created was to offer ladies in Norway a sustainable and more comfortable choice when they have their period. Our whole value chain is within Europe.

6D Tape is unique, patented and active therapeutical tape which works in six directions. It features handles and is skin-friendly, making it well suited for lymphatic therapy, physical therapy, scar treatment and active self-care. The unique 6D handles allow manipulation that stimulates lymph flow, blood circulation, fasciae, scar tissue, muscles and joints. Treatment with 6D Tape will improve recovery from injury, ease joint and muscle pain, reduce nerve compression and swelling, and help with constricting scar tissue. 6D Tape has many therapeutic uses. 6D Tape is effective for treating back, neck and muscle pain, as well as swelling and joints. Manipulating the tape with the handles alleviates pain and reduces swelling by activating the body’s internal cleanup and healing mechanisms. The tape is also suited for treating surgical and traumatic scar tissue and swelling. For example, the tape is excellent at treating repetitive strain injuries, including golfer’s, mouse and tennis elbow, and constricting connective tissue (fascia). 6D Tape works well with patients having Lymphedema, which is a painful chronic condition that causes swelling of limbs and disabilities affecting more than 250 million people worldwide. It has considerable public health significance, characterized by a continuous need for medical treatment, many comorbidities and detrimental effect on patients’ social life and career. It is particularly common among breast cancer survivors with a prevalence of about 40%. The number of lymphedema cases is rising as the number of cancer survivors increases with more effective treatments. The life quality of these people keeps declining dramatically as there are no solutions to manage this condition effectively and live a normal life at the same time. 6D Tape Oy is developing an automated therapy tape system 6D Tape Pro designed for efficient self-care to alleviate lymphedema, as well as pain, scars, and swelling after surgeries and injuries. The tape can be conveniently worn under clothes without interrupting any daily activities. The automated pulsation provides a gentle pressure treatment in planned and natural lymph flow-mimicking intervals. This enables lymphedema patient’s body to function and drain lymph similar to normal body preventing edema. The solution will reduce overall treatment costs and burden on health care systems. Our patent-pending solutions are huge steps forward from any other treatment option available, enabling a lucrative positioning in a €7 billion market. The funding we are seeking is instrumental to take on the high-impact project closing the gap from technology prototype to a clinically validated product suited for mass market. Moreover, the new equity enables to secure enough operational capacity for a successful market launch.

Tal&Dev is an HR-tech startup operating a matching network which leverages AI and proprietary algorithms to create lasting career matches between talents and employers. Their platform is unique with its "candidate spec" that outlines for each applicant not just their (soft & hard) skills and experience but also their ambitions, readiness for effort and workplace preferences thus allowing to vet (two-way) predictive long-term engagement and potential. This helps talents inventory their top skills/development needs and orient themselves towards their best fit career, putting them firmly in the drivers seat. And it allows recruiting teams to avoid endless resume screening and just focus on the best matching candidates as provided by Tal&Dev's proprietary algorithms. More on our services for talents: https://www.talanddev.com/ More on our services for companies: https://www.talanddev.com/companies

Hello, we are 70/30 Digital, modern marketing partner. We believe in companies’ own data, their own media channels and inhouse teams. We help our customers with digitalisation, marketing strategies, technologies that strengthen the customer experience and marketing processes, among other things. We believe in agile methods. Typically, we help our clients with the strategic issues of marketing, digitalization and data, but we also help to put the strategy all the way to practice.

Preglife Connect is a mobile social networking app for (expecting) parents for iOS and Android. We help our users to make friends, feel less lonely and ask questions about parenthood and pregnancy in our friendly and inclusive community. Currently, Preglife Connect is available in 7 European countries (Sweden, Norway, Finland, Germany, Austria, Switzerland, Poland) with over 25,000 users, mostly women between 20-40 years.

StageZero Technologies is a venture backed AI data start-up based in Helsinki on a mission to accelerate the AI revolution. Founded based on ethical principles and operated by AI industry experts, the company is now one of the only EU-based and GDPR-compliant AI data providers. GDPR-compliant data is in many AI cases a bottleneck and 80% of AI project time is allocated to data issues. StageZero Technologies offers enterprise solutions for all aspects of data in AI projects. The company specializes in Natural Language Processing, computer vision, and custom algorithms.